Your browser doesn't support javascript.
loading
Drug-related emergency department visits: external validation of an assessment tool in a general emergency department population.
Nymoen, Lisbeth D; Pettersen, Julie L S; Flatebø, Trude E; Øie, Erik; Viktil, Kirsten K.
Afiliación
  • Nymoen LD; Diakonhjemmet Hospital Pharmacy, Oslo, Norway.
  • Pettersen JLS; Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Flatebø TE; Diakonhjemmet Hospital Pharmacy, Oslo, Norway.
  • Øie E; Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway.
  • Viktil KK; Diakonhjemmet Hospital Pharmacy, Oslo, Norway. kirstkv@farmasi.uio.no.
Int J Clin Pharm ; 2024 Jul 03.
Article en En | MEDLINE | ID: mdl-38958864
ABSTRACT

BACKGROUND:

The process of identifying drug-related hospitalisations is subjective and time-consuming. Assessment tool for identifying hospital admissions related to medications (AT-HARM10) was developed to simplify and objectify this process. AT-HARM10 has not previously been externally validated, thus the predictive precision of the tool is uncertain.

AIM:

To externally validate AT-HARM10 in adult patients admitted to the emergency department (ED).

METHOD:

This retrospective cross-sectional study investigated 402 patients admitted to the ED, Diakonhjemmet Hospital, Oslo, Norway. A trained 5th-year pharmacy student used AT-HARM10 to assess all patients and to classify their ED visits as possibly or unlikely drug-related. Assessment of the same patients by an interdisciplinary expert panel acted as the gold standard. The external validation was conducted by comparing AT-HARM10 classifications with the gold standard.

RESULTS:

According to AT-HARM10 assessments, 169 (42%) patients had a possible drug-related ED visit. Calculated sensitivity and specificity values were 95% and 71%, respectively. Further, positive and negative predictive values were 46% and 98%, respectively. Adverse effects/over-treatment and suboptimal treatment were the issues most frequently overestimated by AT-HARM10 compared with the gold standard.

CONCLUSION:

AT-HARM10 identifies drug-related ED visits with high sensitivity. However, the low positive predictive value indicates that further review of ED visits classified as possible drug-related by AT-HARM10 is necessary. AT-HARM10 can serve as a useful first-step screening that efficiently identifies unlikely drug-related ED visits, thus only a smaller proportion of the patients need to be reviewed by an interdisciplinary expert panel.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Clin Pharm Año: 2024 Tipo del documento: Article País de afiliación: Noruega

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Clin Pharm Año: 2024 Tipo del documento: Article País de afiliación: Noruega